A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902)

International Journal of Clinical Oncology
Yutaka OgataKyushu Study Group of Clinical Cancer (KSCC)

Abstract

This study was designed to evaluate the efficacy and safety of XELOX plus bevacizumab in a Japanese metastatic colorectal cancer population that included elderly patients. This was a multicenter, single-arm, open-label prospective study. The major inclusion criteria were previously untreated metastatic colorectal cancer, presence of measurable lesions, age ≥ 20 years; Eastern Cooperative Oncology Group performance status of 0-2, and adequate organ function. Patients received bevacizumab (7.5 mg/kg on day 1) and XELOX (130 mg/m(2) oxaliplatin on day 1 plus 1,000 mg/m(2) capecitabine b.i.d. on days 1-14) every 3 weeks. The primary endpoint was confirmed objective response rate. The study included 47 patients (male/female 30/17; median age 69 years; age range 38-81 years with 10 patients ≥ 75 years; PS 0/1/2, 40/5/2) enrolled between May 2010 and March 2011. Responses were assessed in 46 eligible patients. The objective response rate was 52.2 % (95 % confidence interval [CI] 37.0-67.1). The median progression-free survival and overall survival were 10.0 months (95 % CI 7.8-12.3) and 34.6 months (95 % CI 19.9-not estimable), respectively. Frequently encountered grade 3 and 4 adverse events in this study were aspartate aminotransfer...Continue Reading

References

Aug 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A de GramontA Bonetti
Sep 28, 2000·The New England Journal of Medicine·L B SaltzL L Miller
Nov 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E Van CutsemUNKNOWN Xeloda Colorectal Cancer Study Group
Sep 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard M GoldbergDaniel J Sargent
May 2, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Van CutsemRafael G Amado
Nov 16, 2007·The New England Journal of Medicine·Derek J JonkerMalcolm J Moore
Apr 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jim CassidyLeonard Saltz
Apr 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Leonard B SaltzJim Cassidy
Jul 22, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard S HochsterEric Hedrick
Dec 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fairooz F KabbinavarOliver Rosen
Feb 7, 2009·The New England Journal of Medicine·Jolien TolCornelis J A Punt
May 18, 2010·International Journal of Cancer. Journal International Du Cancer·Michel DucreuxUNKNOWN GI Group of the French Anti-Cancer Centers
Jul 24, 2010·AJR. American Journal of Roentgenology·Mizuki NishinoAnnick D Van den Abbeele
May 17, 2011·Lancet·Matthew T SeymourUNKNOWN National Cancer Research Institute Colorectal Cancer Clinical Studies Group
Nov 22, 2012·The Lancet Oncology·Jaafar BennounaUNKNOWN ML18147 Study Investigators

❮ Previous
Next ❯

Citations

Aug 15, 2017·Hospital Pharmacy·Meghan J GarrettDominic A Solimando
Sep 1, 2017·Expert Opinion on Drug Safety·Marta Pérez-De-LisManuel Ramos-Casals

❮ Previous
Next ❯

Software Mentioned

SAS

Related Concepts

Related Feeds

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.